Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration has approved Eli Lilly’s Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
Eli Lilly has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis (tadalafil) unit dose patent.
Boehringer Ingelheim (BI) and Eli Lilly are preparing to investigate Jardiance (empagliflozin) tablets for the treatment of people with chronic kidney disease.
International Diabetes Federation (IDF) and Eli Lilly have come together for the second phase of the Bringing Research in Diabetes to Global Environments and Systems programme (BRIDGES 2), reaffirming their commitment to helping people with diabetes effectively manage their condition.
Leigh Ann Pusey will join Eli Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.
Eli Lilly’s MONARCH 3 trial has met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).
Eli Lilly plans to invest $850 million in its U.S. operations in 2017, the company said Friday.
Latino population in the United States of America have higher rates of cardio-metabolic diseases than in rest of the population, said David Kerr, director of Innovation and Research for the William Sansum Diabetes center.
Eli Lilly’s phase 3 double-blind study (MONARCH 2) designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced (locoregionally recurrent or metastatic) breast cancer has met its primary endpoint.
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.